Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
14 05 2020
14 05 2020
Historique:
received:
20
01
2020
accepted:
14
04
2020
entrez:
16
5
2020
pubmed:
16
5
2020
medline:
15
12
2020
Statut:
epublish
Résumé
We set out to determine the usability of serum neurofilament light chain (sNfL), serum glial fibrillary acidic protein (sGFAP), and retinal parameters by using optical coherence tomography (OCT) as reliable biomarkers of the progression of oxaliplatin-induced peripheral neuropathy (OIPN). Forty-three patients scheduled to undergo oxaliplatin-based chemotherapy at the National Cancer Center of Korea between June 2018 and October 2019 were prospectively assessed at baseline, 3 months, and 6 months of chemotherapy. Patients were assessed on clinical scales and underwent OCT, sNfL, and sGFAP level measurement at each follow-up visit. By applying the National Cancer Institute-Common Toxicity Criteria (NCI-CTC), OIPN was classified as grade 1 in 12 (28%) patients, grade 2 in 25 (58%), and grade 3 in 5 (12%) at 6 months of chemotherapy. sNfL levels increased during oxaliplatin administration, while serial sGFAP levels or retinal parameters did not change. Patients with grade-3 OIPN showed significantly higher mean sNfL levels than patients with grade 0-2 OIPN at 6 months of treatment. At 4-6 months after completion of chemotherapy, sNfL levels were significantly reduced compared to the levels at 6 months of chemotherapy. Monitoring of sNfL during chemotherapy can indicate ongoing neuroaxonal injury and the severity of OIPN.
Identifiants
pubmed: 32409710
doi: 10.1038/s41598-020-64511-5
pii: 10.1038/s41598-020-64511-5
pmc: PMC7224372
doi:
Substances chimiques
Biomarkers
0
Neurofilament Proteins
0
neurofilament protein L
0
Oxaliplatin
04ZR38536J
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7995Références
Andre, T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350, 2343–2351, https://doi.org/10.1056/NEJMoa032709 (2004).
doi: 10.1056/NEJMoa032709
pubmed: 15175436
Mols, F. et al. Chemotherapy-induced peripheral neuropathy, physical activity and health-related quality of life among colorectal cancer survivors from the PROFILES registry. Journal of cancer survivorship: research and practice 9, 512–522, https://doi.org/10.1007/s11764-015-0427-1 (2015).
doi: 10.1007/s11764-015-0427-1
Mols, F. et al. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. J Clin Oncol 31, 2699–2707, https://doi.org/10.1200/jco.2013.49.1514 (2013).
doi: 10.1200/jco.2013.49.1514
pubmed: 23775951
Iveson, T. J. et al. 3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trial. The Lancet. Oncology 19, 562–578, https://doi.org/10.1016/s1470-2045(18)30093-7 (2018).
doi: 10.1016/s1470-2045(18)30093-7
pubmed: 29611518
pmcid: 5883334
Postma, T. J. et al. Pitfalls in grading severity of chemotherapy-induced peripheral neuropathy. Ann Oncol 9, 739–744, https://doi.org/10.1023/a:1008344507482 (1998).
doi: 10.1023/a:1008344507482
pubmed: 9739440
Shimozuma, K. et al. Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02. Supportive care in cancer: official journal of the Multinational Association of Supportive Care in Cancer 17, 1483–1491, https://doi.org/10.1007/s00520-009-0613-7 (2009).
doi: 10.1007/s00520-009-0613-7
Gewandter, J. S. et al. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTTION recommendations. Neurology 91, 403–413, https://doi.org/10.1212/wnl.0000000000006083 (2018).
doi: 10.1212/wnl.0000000000006083
pubmed: 30054438
pmcid: 6133627
Matsuoka, A. et al. Quantitative assessment of chemotherapy-induced peripheral neurotoxicity using a point-of-care nerve conduction device. Cancer Sci 107, 1453–1457, https://doi.org/10.1111/cas.13010 (2016).
doi: 10.1111/cas.13010
pubmed: 27412083
pmcid: 5084655
Khalil, M. et al. Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14, 577–589, https://doi.org/10.1038/s41582-018-0058-z (2018).
doi: 10.1038/s41582-018-0058-z
pubmed: 30171200
Quattrini, A. et al. Beta 4 integrin and other Schwann cell markers in axonal neuropathy. Glia 17, 294-306, doi:10.1002/(sici)1098-1136(199608)17:4<294::aid-glia4>3.0.co;2-# (1996).
Notturno, F., Capasso, M., DeLauretis, A., Carpo, M. & Uncini, A. Glial fibrillary acidic protein as a marker of axonal damage in chronic neuropathies. Muscle Nerve 40, 50–54, https://doi.org/10.1002/mus.21323 (2009).
doi: 10.1002/mus.21323
pubmed: 19533665
Rohani, M., Meysamie, A., Zamani, B., Sowlat, M. M. & Akhoundi, F. H. Reduced retinal nerve fiber layer (RNFL) thickness in ALS patients: a window to disease progression. J Neurol 265, 1557–1562, https://doi.org/10.1007/s00415-018-8863-2 (2018).
doi: 10.1007/s00415-018-8863-2
pubmed: 29713825
Gulmez Sevim, D. et al. Evaluation of Retinal Changes in Progressive Supranuclear Palsy and Parkinson Disease. J Neuroophthalmol 38, 151–155, https://doi.org/10.1097/wno.0000000000000591 (2018).
doi: 10.1097/wno.0000000000000591
pubmed: 29240574
Srinivasan, S. et al. Diagnostic capability of retinal thickness measures in diabetic peripheral neuropathy. Journal of optometry 10, 215–225, https://doi.org/10.1016/j.optom.2016.05.003 (2017).
doi: 10.1016/j.optom.2016.05.003
pubmed: 27423690
Meregalli, C. et al. Neurofilament light chain as disease biomarker in a rodent model of chemotherapy induced peripheral neuropathy. Exp Neurol 307, 129–132, https://doi.org/10.1016/j.expneurol.2018.06.005 (2018).
doi: 10.1016/j.expneurol.2018.06.005
pubmed: 29908147
Staff, N. P., Grisold, A., Grisold, W. & Windebank, A. J. Chemotherapy-induced peripheral neuropathy: A current review. Ann Neurol 81, 772–781, https://doi.org/10.1002/ana.24951 (2017).
doi: 10.1002/ana.24951
pubmed: 28486769
pmcid: 5656281
Grothey, A. et al. Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med 378, 1177–1188, https://doi.org/10.1056/NEJMoa1713709 (2018).
doi: 10.1056/NEJMoa1713709
pubmed: 29590544
pmcid: 6426127
Lieu, C. et al. Duration of Oxaliplatin-Containing Adjuvant Therapy for Stage III Colon Cancer: ASCO Clinical Practice Guideline. J Clin Oncol 37, 1436–1447, https://doi.org/10.1200/jco.19.00281 (2019).
doi: 10.1200/jco.19.00281
pubmed: 30986117
Kim, S. H. et al. A Prospective Study of Chronic Oxaliplatin-Induced Neuropathy in Patients with Colon Cancer: Long-Term Outcomes and Predictors of Severe Oxaliplatin-Induced Neuropathy. J Clin Neurol 14, 81–89, https://doi.org/10.3988/jcn.2018.14.1.81 (2018).
doi: 10.3988/jcn.2018.14.1.81
pubmed: 29629544
Velasco, R. et al. Early predictors of oxaliplatin-induced cumulative neuropathy in colorectal cancer patients. J Neurol Neurosurg Psychiatry 85, 392–398, https://doi.org/10.1136/jnnp-2013-305334 (2014).
doi: 10.1136/jnnp-2013-305334
pubmed: 23813745
Alberti, P. Chemotherapy-induced peripheral neurotoxicity - outcome measures: the issue. Expert opinion on drug metabolism & toxicology 13, 241–243, https://doi.org/10.1080/17425255.2017.1258400 (2017).
doi: 10.1080/17425255.2017.1258400
Mattson, N. et al. Association of plasma neurofilament light with neurodegenrative in patients with Alzheimer disease. JAMA Neurol 74, 557–566, https://doi.org/10.1001/jamaneurol.2016.6117 (2017).
doi: 10.1001/jamaneurol.2016.6117
Rohrer, J. D. et al. Serum neurofilament light chain protein is a measure of disease intensity in frontotemporal dementia. Neurology 87, 1329–1336, https://doi.org/10.1212/WNL.0000000000003154 (2016).
doi: 10.1212/WNL.0000000000003154
pubmed: 5047041
pmcid: 5047041
Disanto, G. et al. Serum Neurofilament light: A biomarker of neuronal dagmage in multiple sclerosis. Ann Neurol 81, 857–850, https://doi.org/10.1002/ana.24954 (2017).
doi: 10.1002/ana.24954
pubmed: 28512753
pmcid: 5519945
Yoon, S. Y., Robinson, C. R., Zhang, H. & Dougherty, P. M. Spinal astrocyte gap junctions contribute to oxaliplatin-induced mechanical hypersensitivity. The journal of pain: official journal of the American Pain Society 14, 205–214, https://doi.org/10.1016/j.jpain.2012.11.002 (2013).
doi: 10.1016/j.jpain.2012.11.002
Di Cesare Mannelli, L. et al. Involvement of alpha7 nAChR subtype in rat oxaliplatin-induced neuropathy: effects of selective activation. Neuropharmacology 79, 37–48, https://doi.org/10.1016/j.neuropharm.2013.10.034 (2014).
doi: 10.1016/j.neuropharm.2013.10.034
pubmed: 24225197
Hochster, H. S. et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol 26, 3523–3529, https://doi.org/10.1200/jco.2007.15.4138 (2008).
doi: 10.1200/jco.2007.15.4138
pubmed: 18640933
Giantonio, B. J. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25, 1539–1544, https://doi.org/10.1200/jco.2006.09.6305 (2007).
doi: 10.1200/jco.2006.09.6305
pubmed: 17442997
Ye, L. C. et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 31, 1931–1938, https://doi.org/10.1200/jco.2012.44.8308 (2013).
doi: 10.1200/jco.2012.44.8308
pubmed: 23569301
Argyriou, A. A. et al. Peripheral neurotoxicity of oxaliplatin in combination with 5-fluorouracil (FOLFOX) or capecitabine (XELOX): a prospective evaluation of 150 colorectal cancer patients. Ann Oncol 23, 3116–3122, https://doi.org/10.1093/annonc/mds208 (2012).
doi: 10.1093/annonc/mds208
pubmed: 22865779
Trotti, A. et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars in radiation oncology 13, 176–181, https://doi.org/10.1016/s1053-4296(03)00031-6 (2003).
doi: 10.1016/s1053-4296(03)00031-6
pubmed: 12903007
Kim, H. Y. et al. Reliability and validity of the Korean version of the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire to assess Chemotherapy-induced peripheral neuropathy. Journal of Korean Academy of Nursing 44, 735–742, https://doi.org/10.4040/jkan.2014.44.6.735 (2014).
doi: 10.4040/jkan.2014.44.6.735
pubmed: 25608551
Postma, T. J. et al. The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. European journal of cancer (Oxford, England: 1990) 41, 1135–1139, https://doi.org/10.1016/j.ejca.2005.02.012 (2005).
doi: 10.1016/j.ejca.2005.02.012